Findings

What do systematic reviews say?

25 questions · 25 findings · 2 reviews · Gynaecology and Fertility

Sort:Best matchNewest Highest certainty Download CSV

No studies found 5 · 20%GRADE not reported 0 · 0%Very low 7 · 28%Low 7 · 28%Moderate 6 · 24%High 0 · 0%

Myo‐inositol vs metformin

Live birth · subfertile women with polycystic ovary syndrome

The review found no eligible studies for this question.

1 finding from 1 review

Inositol for subfertile women with polycystic ovary syndrome 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Myo‐inositol vs metformin

Adverse events · subfertile women with polycystic ovary syndrome

The review found no eligible studies for this question.

1 finding from 1 review

Inositol for subfertile women with polycystic ovary syndrome 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Myo‐inositol vs metformin

Clinical pregnancy · subfertile women with polycystic ovary syndrome

It is very uncertain whether myo‐inositol changes clinical pregnancy compared with an insulin‐sensitising agent (metformin) (very low certainty).

1 finding from 1 review

Inositol for subfertile women with polycystic ovary syndrome 2018 · Cochrane Headline outcomes only
OR 1.91 [0.81, 4.49]
1 study · 120 participants
Very low

Myo‐inositol vs metformin

Ovulation · subfertile women with polycystic ovary syndrome

It is very uncertain whether myo‐inositol changes ovulation compared with an insulin‐sensitising agent (metformin) (very low certainty).

1 finding from 1 review

Inositol for subfertile women with polycystic ovary syndrome 2018 · Cochrane Headline outcomes only
OR 1.86 [0.89, 3.87]
1 study · 120 participants
Very low

Metformin vs placebo or no treatment

Live birth rate per woman · Women with polycystic ovary syndrome, oligo amenorrhoea and subfertility

Metformin showed no clear difference in live birth rate per woman compared with placebo or no treatment (low certainty).

1 finding from 1 review

Insulin‐sensitising drugs (metformin, rosiglitazone, pioglitazone, D‐chiro‐inositol) for women with polycystic ovary… 2017 · Cochrane Headline outcomes only
OR 1.59 [1, 2.51]
4 studies · 435 participants
Low

Metformin combined with clomiphene citrate vs clomiphene

Menstrual frequency per woman · women with polycystic ovary syndrome

The review found no eligible studies for this question.

1 finding from 1 review

Insulin‐sensitising drugs (metformin, rosiglitazone, pioglitazone, D‐chiro‐inositol) for women with polycystic ovary… 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Metformin combined with clomiphene citrate vs clomiphene

Ovulation rate · women with polycystic ovary syndrome

Metformin combined with clomiphene citrate probably leads to higher ovulation rate per woman compared with clomiphene citrate alone (moderate certainty).

1 finding from 1 review · compare the 2 reviews

Insulin‐sensitising drugs (metformin, rosiglitazone, pioglitazone, D‐chiro‐inositol) for women with polycystic ovary… 2017 · Cochrane Headline outcomes only
OR 1.57 [1.28, 1.92]
21 studies · 1624 participants
Moderate

Metformin combined with clomiphene citrate vs clomiphene

Miscarriage · women with polycystic ovary syndrome

Metformin combined with clomiphene citrate may leads to higher miscarriage rate per woman compared with clomiphene citrate alone (low certainty).

1 finding from 1 review · compare the 2 reviews

Insulin‐sensitising drugs (metformin, rosiglitazone, pioglitazone, D‐chiro‐inositol) for women with polycystic ovary… 2017 · Cochrane Headline outcomes only
OR 1.59 [1.03, 2.46]
9 studies · 1096 participants
Low

Metformin vs clomiphene

Live birth rate per woman aParticipants with BMI < 30 kg/m2 or ≤ 32 kg/m2 · women with polycystic ovary syndrome

It is very uncertain whether metformin changes live birth rate per woman Participants with BMI < 30 kg/m2 or ≤ 32… compared with clomiphene citrate (very low certainty).

1 finding from 1 review · compare the 2 reviews

Insulin‐sensitising drugs (metformin, rosiglitazone, pioglitazone, D‐chiro‐inositol) for women with polycystic ovary… 2017 · Cochrane Headline outcomes only
OR 1.71 [1, 2.94]
3 studies · 241 participants
Very low

Metformin vs clomiphene

Live birth rate per woman aParticipants with BMI ≥ 30 kg/m2 · women with polycystic ovary syndrome

It is very uncertain whether metformin changes live birth rate per woman Participants with BMI ≥ 30 kg/m2a compared with clomiphene citrate (very low certainty).

1 finding from 1 review · compare the 2 reviews

Insulin‐sensitising drugs (metformin, rosiglitazone, pioglitazone, D‐chiro‐inositol) for women with polycystic ovary… 2017 · Cochrane Headline outcomes only
OR 0.3 [0.17, 0.52]
2 studies · 500 participants
Very low

Metformin vs clomiphene

Gastrointestinal adverse events · women with polycystic ovary syndrome

The review found no eligible studies for this question.

1 finding from 1 review · compare the 2 reviews

Insulin‐sensitising drugs (metformin, rosiglitazone, pioglitazone, D‐chiro‐inositol) for women with polycystic ovary… 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Metformin vs clomiphene

Clinical pregnancy rate per woman Participants with BMI < 30 kg/m2 or ≤ 32 kg/m2a · women with polycystic ovary syndrome

It is very uncertain whether metformin changes clinical pregnancy rate per woman Participants with BMI < 30 kg/m2… compared with clomiphene citrate (very low certainty).

1 finding from 1 review · compare the 2 reviews

Insulin‐sensitising drugs (metformin, rosiglitazone, pioglitazone, D‐chiro‐inositol) for women with polycystic ovary… 2017 · Cochrane Headline outcomes only
OR 1.56 [1.05, 2.33]
5 studies · 490 participants
Very low

Metformin vs clomiphene

Clinical pregnancy rate per woman aParticipants with BMI ≥ 30 kg/m2 · women with polycystic ovary syndrome

It is very uncertain whether metformin changes clinical pregnancy rate per woman Participants with BMI ≥ 30 kg/m2a compared with clomiphene citrate (very low certainty).

1 finding from 1 review · compare the 2 reviews

Insulin‐sensitising drugs (metformin, rosiglitazone, pioglitazone, D‐chiro‐inositol) for women with polycystic ovary… 2017 · Cochrane Headline outcomes only
OR 0.34 [0.21, 0.55]
2 studies · 500 participants
Very low

Metformin vs clomiphene

Menstrual frequency per woman · women with polycystic ovary syndrome

The review found no eligible studies for this question.

1 finding from 1 review

Insulin‐sensitising drugs (metformin, rosiglitazone, pioglitazone, D‐chiro‐inositol) for women with polycystic ovary… 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Metformin vs clomiphene

Ovulation rate per woman fParticipants with BMI < 30 kg/m2 · women with polycystic ovary syndrome

Metformin showed no clear difference in ovulation rate per woman Participants with BMI < 30 kg/m2b compared with clomiphene citrate (low certainty).

1 finding from 1 review · compare the 2 reviews

Insulin‐sensitising drugs (metformin, rosiglitazone, pioglitazone, D‐chiro‐inositol) for women with polycystic ovary… 2017 · Cochrane Headline outcomes only
OR 0.81 [0.51, 1.28]
4 studies · 312 participants
Low

Metformin vs placebo or no treatment

Gastrointestinal adverse events · Women with polycystic ovary syndrome, oligo amenorrhoea and subfertility

Metformin probably leads to higher adverse events (gastrointestinal) per woman compared with placebo or no treatment (moderate certainty).

1 finding from 1 review

Insulin‐sensitising drugs (metformin, rosiglitazone, pioglitazone, D‐chiro‐inositol) for women with polycystic ovary… 2017 · Cochrane Headline outcomes only
OR 4.76 [3.06, 7.41]
7 studies · 670 participants
Moderate

Metformin vs clomiphene

Ovulation rate per woman fParticipants with BMI ≥ 30 kg/m2 · women with polycystic ovary syndrome

Metformin may leads to lower ovulation rate per woman Participants with BMI ≥ 30 kg/m2b compared with clomiphene citrate (low certainty).

1 finding from 1 review · compare the 2 reviews

Insulin‐sensitising drugs (metformin, rosiglitazone, pioglitazone, D‐chiro‐inositol) for women with polycystic ovary… 2017 · Cochrane Headline outcomes only
OR 0.29 [0.2, 0.43]
2 studies · 500 participants
Low

Metformin vs clomiphene

Miscarriage · women with polycystic ovary syndrome

It is very uncertain whether metformin changes miscarriage rate per woman compared with clomiphene citrate (very low certainty).

1 finding from 1 review

Insulin‐sensitising drugs (metformin, rosiglitazone, pioglitazone, D‐chiro‐inositol) for women with polycystic ovary… 2017 · Cochrane Headline outcomes only
OR 0.92 [0.5, 1.67]
5 studies · 741 participants
Very low

Metformin vs placebo or no treatment

Clinical pregnancy rate · Women with polycystic ovary syndrome, oligo amenorrhoea and subfertility

Metformin probably leads to higher clinical pregnancy rate per woman compared with placebo or no treatment (moderate certainty).

1 finding from 1 review

Insulin‐sensitising drugs (metformin, rosiglitazone, pioglitazone, D‐chiro‐inositol) for women with polycystic ovary… 2017 · Cochrane Headline outcomes only
OR 1.93 [1.42, 2.64]
9 studies · 1027 participants
Moderate

Metformin vs placebo or no treatment

Menstrual frequency per woman · Women with polycystic ovary syndrome, oligo amenorrhoea and subfertility

Metformin may leads to higher menstrual frequency per woman compared with placebo or no treatment (low certainty).

1 finding from 1 review

Insulin‐sensitising drugs (metformin, rosiglitazone, pioglitazone, D‐chiro‐inositol) for women with polycystic ovary… 2017 · Cochrane Headline outcomes only
OR 1.72 [1.14, 2.61]
7 studies · 427 participants
Low